2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

La Merie Publishing released on March 11, 2021 the 15th edition of reports about sales of Blockbuster Biologics. This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2020. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 5, 2021. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases as constant exchange rates).

2020 sales data of biosimilar antibodies and proteins are included in the report provided that the data were published by the companies. This report also includes for the first time sales data of new biologic modalities such as gene and cell therapy and RNAi.

Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.

Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies.

Development of sales of antibody-drug conjugates are also presented for the first time.

A total of 62 biologic therapeutics reached blockbuster status with 2020 sales exceeding US$ 1 bln. Sales of 20 new antibody and protein products for the year 2020 were included for the first time in this report. Antibody sales represented more than 75% of total biologics sales in 2020. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2020 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2020.